MPM BioVentures IV
MPM Capital began investing its fourth venture fund, the MPM BioVentures IV Fund, in 2Q 2006. With committed capital of $550 million, the MPM BioVentures IV Fund will ultimately comprise a portfolio of approximately 20 companies, with approximately 85% focused on biotechnology and pharmaceutical products and 15% focused on medical device companies. The fund’s preferred investment size will be in the range of $20 million - $50 million per company. The fund will consider for initial investment companies across a wide range in terms of stage and will also consider PIPEs. From a geographic perspective, approximately 20% of the fund’s investments will be made outside the U.S., primarily in Europe and in Asia. The uniquely broad and deep team that has been assembled at MPM Capital to build and manage the fund’s portfolio possesses is characterized not only by its investment and scientific prowess but also by its expertise in building leading clinical and commercial stage companies. MPM BioVentures IV expects to continue to lead the majority of its investments and take an active role as board members in the portfolio companies.